CN102018754B - Vaginal effervescent tablet and making process thereof - Google Patents
Vaginal effervescent tablet and making process thereof Download PDFInfo
- Publication number
- CN102018754B CN102018754B CN 200910170297 CN200910170297A CN102018754B CN 102018754 B CN102018754 B CN 102018754B CN 200910170297 CN200910170297 CN 200910170297 CN 200910170297 A CN200910170297 A CN 200910170297A CN 102018754 B CN102018754 B CN 102018754B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- tablets
- mixing
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 3
- 239000007938 effervescent tablet Substances 0.000 title abstract 3
- 239000008187 granular material Substances 0.000 claims abstract description 13
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 11
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 9
- 229910021538 borax Inorganic materials 0.000 claims abstract description 9
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 9
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims abstract description 3
- 229940097275 indigo Drugs 0.000 claims abstract description 3
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000006071 cream Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 210000001215 vagina Anatomy 0.000 claims description 12
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 10
- 206010046914 Vaginal infection Diseases 0.000 abstract description 5
- 201000008100 Vaginitis Diseases 0.000 abstract description 3
- 230000003628 erosive effect Effects 0.000 abstract description 3
- 241000213006 Angelica dahurica Species 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract 4
- 210000004400 mucous membrane Anatomy 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000212948 Cnidium Species 0.000 abstract 1
- 244000148137 Patrinia villosa Species 0.000 abstract 1
- 235000019109 Patrinia villosa Nutrition 0.000 abstract 1
- 241000246044 Sophora flavescens Species 0.000 abstract 1
- 229940037003 alum Drugs 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 102000011759 adducin Human genes 0.000 description 3
- 108010076723 adducin Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 241000588902 Zymomonas mobilis Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940007046 shigella dysenteriae Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940089230 nystatin vaginal tablet Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Abstract
The invention relates to a traditional Chinese medicine for the treatment of vaginitis and cervical erosion, especially to a vaginal effervescent tablet and its making process. The vaginal effervescent tablets comprise, by weight, from 200 to 900 parts of sophora flavescens, from 100 to 600 parts of Chinese angelica, from100 to 500 parts of common cnidium fruit, from 100 to 500 parts of natural indigo, from 50 to 300 parts of alum, from 20 to 200 parts of borax, from 50 to 300 parts of diversifolious patrinia root and from 5 to 100 parts of borneol. The ingredients are extracted, concentrated, and dried into granules, and then pressed into oval-shaped tablets. After gynaecology local use, tablets in the invention disintegrate in fast speed, take effect quickly, uniformly distribute in cervical and vaginal, infiltrate into the deep folds of mucous membrane, and tablets are characterized by complete absorption, no hurt to the mucous membrane, sanitation and easy storage. In addition, the tablets do not result in resistance to medicine and recurrence hardly occurs after cure.
Description
Technical field
The present invention relates to a kind of Chinese medicine for the treatment of vaginitis, cervical erosion, the moon is a kind of vagina effervescence and processing technology especially.
Background technology
Gynecological infectious diseases is that class commonly encountered diseases and a frequently-occurring disease, particularly colpitis mycotica, cervical erosion sickness rate are very high.Reproductive tract infection is modal common gynecological disease (prevalence is 42.9%), wherein has 83.1% women to suffer from a kind of infection, and 15.1% women suffers from two kinds of infection, and 1.8% women suffers from 3 kinds and above reproductive tract infection simultaneously.The treatment of this disease mainly contains two kinds of methods: a kind of is local topical administration, and medicine commonly used has nystatin vaginal tablet, suppository, clotrimazole etc., and this several drugs therapeutic effect is unsatisfactory, easily produces drug resistance, easily recurrence, and local excitation is larger.Another kind is oral administration, and such as Oral Ketoconazole, fluconazol etc., although the oral medicine taking convenience, side effect is obvious, such as gastrointestinal reaction, headache and liver toxicity.
Summary of the invention
The objective of the invention is in order to overcome existing is that medicine for external use produces easily that the drug resistance local excitation is large, the obvious defective of oral medicine side effect, invents a kind of vagina effervescence and processing technology thereof of utilizing Radix Sophorae Flavescentis, Radix Angelicae Sinensis, Fructus Cnidii, Indigo Naturalis, Alumen, Borax, Radix Patriniae heterophyllae, Borneolum Syntheticum to make.
The objective of the invention is to realize by following technical scheme:
Described vagina effervescence is mixed and is formed by Radix Sophorae Flavescentis, Radix Angelicae Sinensis, Fructus Cnidii, Indigo Naturalis, Alumen, Borax, Radix Patriniae heterophyllae, Borneolum Syntheticum, and each component is by weight ratio:
200～900 parts of Radix Sophorae Flavescentiss,
100～600 parts of Radix Angelicae Sinensis,
100～500 parts of Fructus Cnidiis,
100～500 parts of Indigo Naturaliss,
50～300 parts in Alumen,
20～200 parts of Boraxs,
50～300 parts of Radix Patriniae heterophyllaes,
5～100 parts of Borneolum Syntheticums.
The processing technology of described vagina effervescence may further comprise the steps:
Get Radix Sophorae Flavescentis, Radix Angelicae Sinensis, Fructus Cnidii, Radix Patriniae heterophyllae, decoct with water two～three times, decocted 1～3 hour at every turn, adding the water multiple is 8～15 times, filter, and merging filtrate, being concentrated into relative density is 1.10～1.20g/cm
3(60 ℃) add 95% ethanol and make and contain alcohol amount and reach 60%～80%, placed 12 hours～24 hours, and filtration, decompression recycling ethanol, being concentrated into relative density is 1.15～1.35g/cm
3Thick paste, vacuum drying is pulverized and made dried cream powder, and is for subsequent use;
Claim that 1/2 of dried cream powder gross weight is measured, the tartaric acid mixing of 1/2 amount, Alumen (one or several in three components) and 100～600 weight portions of Indigo Naturalis gross weight, 3%～8% polyvinylpyrrolidone mixes 70%～95% alcohol granulation, 50-70 ℃ of oven dry gets dried granule, and be for subsequent use;
Take by weighing 1/2 amount of dried cream powder gross weight, 1/2 amount of Indigo Naturalis gross weight and the sodium bicarbonate mixing of Borax (one or several in three components) and 100～600 weight portions; 3%～8% polyvinylpyrrolidone mixes 70%～95% alcohol granulation; 50-70 ℃ of oven dry; granulate; with above-mentioned dried granule mixing; the magnesium stearate that adds Borneolum Syntheticum and 1～100 weight portion, mixing is pressed ellipse slice.
Good effect of the present invention is as follows:
(1) the present invention adopts according to Traditional Chinese medical theory, take heat clearing and damp drying, promoting blood flow to regulate menstruation, detoxifying and relieving itching as major function, adopt the vagina administration mode, can avoid first pass effect, blood drug level steadily, outside the characteristics such as long action time, application be convenient, also because there is not the such keratinization of skin in vaginal mucosa, and blood capillary is abundant under the mucosa, the characteristics such as make mucosa delivery have that dosage is little, bioavailability is high and action time is fast.
(2) female private part pruritus, inflammation belong to the category of the traditional Chinese medical science " pudendal pruritus leukorrheal diseases ", and the traditional Chinese medical science thinks it mainly is because of damp and hot pent-up, or infects due to the evil poison, when the rule take heat clearing and damp drying, promoting blood flow to regulate menstruation, detoxifying and relieving itching as health-care recovery.Radix Sophorae Flavescentis heat clearing and damp drying, parasite killing among the present invention; The Fructus Cnidii dispeiling pathogenic wind and removing dampness, killing parasites for relieving itching; Chinese angelica blood supplementing is invigorated blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation; Alumen removing dampness sore, hemostasisization is rotten; The Borax heat-clearing and toxic substances removing; The Radix Patriniae heterophyllae heat clearing and damp drying, hemostasis, leukorrhagia stopping; The Indigo Naturalis heat-clearing and toxic substances removing; The through sick institute of property medicine carrying that Borneolum Syntheticum is walked to alter with its fragrance.
(3) gynecological is local have after using disintegration rate fast, rapid-action, be uniformly distributed in cervix uteri, vagina, and can infiltrate mucosa gauffer deep, have absorption and fully, do not hinder the characteristics such as mucosa, clean hygiene, storage be easy, have no drug resistance, be difficult for recurrence after curing.
(4) the present invention utilizes the soda acid fast reaction that the effective ingredient such as Radix Angelicae Sinensis are distributed in the disease sites equably, directly brings into play rapidly curative effect.Show resistance that can be effective and kill intravaginal bacteria infection through modern pharmacodynamics test.
The specific embodiment
Embodiment 1:
Get Radix Sophorae Flavescentis 300g, Radix Angelicae Sinensis 360g, Fructus Cnidii 250g, Radix Patriniae heterophyllae 120g, decoct with water twice, decocted 1 hour at every turn, adding the water multiple is 10,8 times, filter, and merging filtrate, being concentrated into relative density is 1.15g/cm
3(60 ℃) add 95% ethanol and make and contain alcohol amount and reach 65%, placed 12 hours, and filtration, decompression recycling ethanol, being concentrated into relative density is 1.20g/cm
3Thick paste, vacuum drying is pulverized and made dried cream powder, and is for subsequent use;
Take by weighing 1/2 amount, Indigo Naturalis 150g, Alumen 210g and the tartaric acid 200g mixing of dried cream powder gross weight, 3% polyvinylpyrrolidone mixes 90% alcohol granulation, and 65 ℃ of oven dry get dried granule, and are for subsequent use;
Take by weighing 1/2 amount, Indigo Naturalis 150g and Borax 45g and the sodium bicarbonate 150g mixing of dried cream powder gross weight, 3%～8% polyvinylpyrrolidone mixes 70%～95% alcohol granulation, 65 ℃ of oven dry; granulate with above-mentioned dried granule mixing, adds Borneolum Syntheticum 10g, magnesium stearate 3g; mixing is pressed ellipse slice.
Embodiment 2:
Get Radix Sophorae Flavescentis 40kg, Radix Angelicae Sinensis 28kg, Fructus Cnidii 15kg, Radix Patriniae heterophyllae 10kg, decoct with water three times, each decocting time is 2 hours, 1 hour, 1 hour, and adding the water multiple is 10,8,8 times, filter, and merging filtrate, being concentrated into relative density is 1.20g/cm
3(60 ℃) add 95% ethanol and make and contain alcohol amount and reach 70%, placed 12 hours, and filtration, decompression recycling ethanol, being concentrated into relative density is 1.25g/cm
3Thick paste, vacuum drying is pulverized and made dried cream powder, and is for subsequent use;
Take by weighing 1/2 amount, Alumen 26kg and the tartaric acid 17.8kg mixing of dried cream powder gross weight, 4% polyvinylpyrrolidone mixes 90% alcohol granulation, and 70 ℃ of oven dry get dried granule, and are for subsequent use;
Take by weighing 1/2 amount, Borax 6kg and the sodium bicarbonate 22kg mixing of dried cream powder gross weight, 4% polyvinylpyrrolidone mixes 90% alcohol granulation, 70 ℃ of oven dry; granulate with above-mentioned dried granule mixing, adds Borneolum Syntheticum 1.5kg, magnesium stearate 0.3kg; mixing is pressed ellipse slice.
In Vitro Bacteriostasis experimental result of the present invention is as follows:
Utilize medicine of the present invention (embodiment 1) to carry out In Vitro Bacteriostasis experiment, matched group amino benzylpenicillin injection; Cultivate escherichia coli, Bacillus proteus, Shigella dysenteriae, Salmonella typhi, Aerugo first Zymomonas mobilis, Candida albicans at agar culture medium respectively, the medicine (250mg/ml) of embodiment 1 and the medicine (50ug/ml) of matched group are carried out bacteriostatic experiment with conventional method respectively, test result such as following table:
| Antibacterial | The strain number | MIC(mg/ml) | MIC 50 (mg/ml) | MIC 90 (mg/ml) |
| Escherichia coli | 30 | 1.12～37.5 | 2.5 | 5 |
| Bacillus proteus | 30 | 7.57～120 | 31.5 | 62.5 |
| Shigella dysenteriae | 20 | 7.57～120 | 31.5 | 62.5 |
| Salmonella typhi | 40 | 3.55～65 | 3.55 | 25 |
| Aerugo first Zymomonas mobilis | 20 | 62.5～250 | 62.5 | 125 |
| Candida albicans | 30 | 1.25～125 | 2.5 | 17.5 |
Medicine of the present invention has obvious inhibitory action to Candida albicans.
Clinical observation on the therapeutic effect result of the present invention is as follows:
Colpitis mycotica patient's 200 examples are divided two groups, every group of 100 examples, and the experimental group medicine of embodiment 2, an a slice is every other day used once, is used in conjunction 15 days according to curative effect; The matched group nystatin, a slice 500000 units, every night once, vagina drug applying is used in conjunction 10 days.Clinical efficacy evaluation: cure: symptom, sign disappear, and microscopy is negative.Produce effects: symptom, sign obviously alleviate, and microscopy is negative.Effectively: symptom, sign alleviate, and microscopy is positive.Invalid: symptom, sign are without changing or increasing the weight of, and microscopy is positive.Two groups of medication results such as following table:
| Group | Example number (example) | Cure (example) | Produce effects (example) | Effectively (example) | Invalid (example) | Total effective rate (%) |
| Experimental group | 100 | 88 | 7 | 2 | 3 | 97 |
| Matched group | 100 | 70 | 5 | 3 | 22 | 78 |
Experimental group total effective rate 97%, matched group are 78%, and difference has significance (p＜0.05), adopt Drug therapy vaginitis of the present invention remarkable than the nystatin effect, and curative effect is sure, has no adverse reaction.
Claims (2)
1. vagina effervescence is characterized in that: described vagina effervescence is mixed and is formed by Radix Sophorae Flavescentis, Radix Angelicae Sinensis, Fructus Cnidii, Indigo Naturalis, Alumen, Borax, Radix Patriniae heterophyllae, Borneolum Syntheticum, and each component is by weight ratio:
200～900 parts of Radix Sophorae Flavescentiss,
100～600 parts of Radix Angelicae Sinensis,
100～500 parts of Fructus Cnidiis,
100～500 parts of Indigo Naturaliss,
50～300 parts in Alumen,
20～200 parts of Boraxs,
50～300 parts of Radix Patriniae heterophyllaes,
5～100 parts of Borneolum Syntheticums.
2. the processing technology of vagina effervescence according to claim 1, it is characterized in that: the processing technology of described vagina effervescence may further comprise the steps:
Get Radix Sophorae Flavescentis, Radix Angelicae Sinensis, Fructus Cnidii, Radix Patriniae heterophyllae, decoct with water two～three times, decocted 1～3 hour at every turn, adding the water multiple is 8～15 times, filter, and merging filtrate, being concentrated into relative density is 1.10～1.20g/cm
3, temperature is 60 ℃, adds 95% ethanol and makes and contain the alcohol amount and reach 60%～80%, placed 12 hours～24 hours, filtration, decompression recycling ethanol, being concentrated into relative density is 1.15～1.35g/cm
3Thick paste, vacuum drying is pulverized and made dried cream powder, and is for subsequent use;
Claim that 1/2 of dried cream powder gross weight is measured, the tartaric acid mixing of 1/2 amount, Alumen and 100～600 weight portions of Indigo Naturalis gross weight, 3%～8% polyvinylpyrrolidone mixes 70%～95% alcohol granulation, and 50-70 ℃ of oven dry gets dried granule, and be for subsequent use;
Take by weighing 1/2 amount of dried cream powder gross weight, 1/2 amount of Indigo Naturalis gross weight and the sodium bicarbonate mixing of Borax and 100～600 weight portions; 3%～8% polyvinylpyrrolidone mixes 70%～95% alcohol granulation; 50-70 ℃ of oven dry; granulate; with above-mentioned dried granule mixing; the magnesium stearate that adds Borneolum Syntheticum and 1～100 weight portion, mixing is pressed ellipse slice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910170297 CN102018754B (en) | 2009-09-11 | 2009-09-11 | Vaginal effervescent tablet and making process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910170297 CN102018754B (en) | 2009-09-11 | 2009-09-11 | Vaginal effervescent tablet and making process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102018754A CN102018754A (en) | 2011-04-20 |
| CN102018754B true CN102018754B (en) | 2013-04-24 |
Family
ID=43860804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910170297 Active CN102018754B (en) | 2009-09-11 | 2009-09-11 | Vaginal effervescent tablet and making process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102018754B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102218100B (en) * | 2011-05-23 | 2012-06-27 | 哈尔滨医科大学 | Effervescent tablet for treating cervical cancer and gynecological inflammation and preparation method thereof |
| CN103301373B (en) * | 2013-07-01 | 2015-04-08 | 朱月英 | Pharmaceutical composition for treating postpartum perineal mucosal lesions |
| CN103830480B (en) * | 2014-03-21 | 2016-10-12 | 河南中医学院 | A kind of Chinese medicine film postoperative for cervical erosion |
| CN105709001A (en) * | 2016-04-07 | 2016-06-29 | 甘起伍 | Anti-bacterial effervescent tablets and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1179971A (en) * | 1997-09-09 | 1998-04-29 | 张惠媛 | Traditional Chinese medicine for curing leukoplakia vulvae of gynecopathy |
-
2009
- 2009-09-11 CN CN 200910170297 patent/CN102018754B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1179971A (en) * | 1997-09-09 | 1998-04-29 | 张惠媛 | Traditional Chinese medicine for curing leukoplakia vulvae of gynecopathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102018754A (en) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102160887B (en) | Medicament for treating gynecological inflammation and preparation method thereof | |
| CN101347541B (en) | Medicament for treating gynecology disease and dermatopathy and preparation thereof | |
| CN102697961B (en) | Gynecological cleaning solution and preparation method thereof | |
| CN101049415A (en) | Preparation of Chinese traditional medicine for treating inflammation of department of gynecology | |
| CN103070963B (en) | Traditional Chinese medicine preparation for treating candida albicans infection diseases | |
| CN101884754A (en) | External Chinese medicinal preparation for treating gynecological inflammation | |
| CN102552769B (en) | Medicine for treating vaginitis and preparation method thereof | |
| CN102018754B (en) | Vaginal effervescent tablet and making process thereof | |
| CN101401862A (en) | External-use gelling agent for treating cervical erosion | |
| CN102846858A (en) | Antibacterial pharmaceutical composition | |
| CN102631589A (en) | Penyanxiao enema and preparation method thereof | |
| CN102210773B (en) | Chinese medicinal cataplasm for treating infantile pneumonia, preparation method thereof and application thereof | |
| CN103610776A (en) | Soup for nursing and cleaning gynaecological vulvae | |
| CN110393768A (en) | A kind of combined traditional Chinese medicine dabbling drug of Gilt Uterus anti-inflammatory and its preparation method and application | |
| CN105012818A (en) | Composition for treating gynecological inflammation and preparation and preparation method thereof | |
| CN102600456B (en) | Bioadhesive vaginal plug for treating vaginitis and cervicitis as well as preparation method of bioadhesive vaginal plug | |
| CN101391065A (en) | Compound momordica seed pepper soup for treating urgent chronic pelvic inflammatory disease | |
| CN101972451B (en) | Compound infusion preparation of Chinese herbal medicines and western medicines for treating cow hysteritis and preparation method thereof | |
| CN105412861A (en) | Traditional Chinese medicine composition for treating tubal nowhere and preparation method thereof | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN100592912C (en) | Externally used compound preparation for treating gynecology disease and method for preparing the same | |
| CN101829188B (en) | Medicament for treating urinary infection and lithiasis | |
| CN104825852A (en) | Tibetan medicine composition, preparation method and application thereof | |
| CN104547325A (en) | Medicinal composition for treating chronic idiopathic urticaria and application thereof | |
| CN103893300A (en) | Traditional Chinese medicine composition for treating dairy cow endometritis, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Qiang Document name: payment instructions |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Room 402, Unit 3, Building 1, Ningxinyuan, Changping District, Beijing, 102200 Patentee after: Li Qiang Address before: 135000 Meihekou province Jilin City Fumin Street Committee 3 group 2 Patentee before: Li Qiang |